Company intelligence
Moffitt Cancer Center
To contribute to the prevention and cure of cancer
About Moffitt Cancer Center
At Moffitt Cancer Center, we come face-to-face with cancer every day, but we also see courage. And it inspires us to be the safest and best place for cancer care – to bring greater hope to every patient we serve. It’s why we’ve been continually named One of the Top Places to Work in the Tampa Bay Area. As the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, Moffitt employs some of the best and brightest minds from around the world. Moffitt is the top cancer hospital in Florida according to U.S. News & World Report and has been nationally ranked since 1999. Because working at Moffitt is both a career and a mission: to contribute to the prevention and cure of cancer. Join a dedicated, diverse and inclusive team of over 10,000 to be a part of the Courageous future we envision.
Verified activity
Signals from Moffitt Cancer Center
21 published signals
Research & Knowledge
Moffitt Cancer Center published a new paper led by Leonid Kostrykin and Beatriz Serrano-Solano PhD discussing bioimage analysis and management software tools for the Galaxy Project.
Reported by Jeremy Goecks
Presence & Recognition
Moffitt Cancer Center remains Florida's longest-established National Cancer Institute-designated Comprehensive Cancer Center more than two decades after its designation in 2001.
Reported by Moffitt Cancer Center
Research & Knowledge
Moffitt Cancer Center published a study in Nature Chemical Biology revealing that the sugars on tumor-fighting T cells can influence whether they survive inside a tumor.
Reported by Patrick Hwu
Presence & Recognition
Moffitt Cancer Center is attending the Cell Coast Conference to discover the future of oncology.
Reported by Moffitt Cancer Center
People
Moffitt Cancer Center is hiring a Director of Epic Research to lead the design, implementation, and ongoing optimization of research functionality within the Epic system to support Moffitt's research workflows and initiatives.
Reported by Moffitt Cancer Center
Products & Services
Moffitt Cancer Center designed Value Governance™ as an accountability architecture for the three stages of value governance.
Reported by Roderick Harris, MBA
Presence & Recognition
Moffitt Cancer Center is test-driving CAR T-Cell therapy in collaboration with the FDA.
Reported by Bichoy Gabra
Legal & Regulatory
Moffitt Cancer Center announced that the FDA approved Decnupaz (pivekimab sunirine-pvzy), a CD123-directed antibody and alkylating agent conjugate, for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) on May 27, 2026.
Reported by Bichoy Gabra
Technology & Infrastructure
Moffitt Cancer Center asked AI to model out the levers that drive operational outcomes at an NCI Cancer Center like Moffitt.
Reported by Clayton Daley
Presence & Recognition
Moffitt Cancer Center hosted an episode of The ImmunoVerse featuring Dr. Yvonne Chen discussing engineering principles shaping CAR T-cell therapy.
Reported by Patrick Hwu
Legal & Regulatory
Moffitt Cancer Center announced that the FDA approved Rasonque (daraxonrasib) as a RAS inhibitor for metastatic pancreatic cancer on August 26, 2026, delivering a new treatment option months ahead of schedule.
Reported by Bichoy Gabra
Partnerships
Moffitt Cancer Center is working with Reimagine Care and Cureety to build better comprehensive triage models based on disease and treatment specific algorithms.
Reported by Timothy Hembree
Research & Knowledge
Moffitt Cancer Center published a post discussing the six stages of an investment's life and formal governance covering the first three stages in health systems.
Reported by Roderick Harris, MBA
Presence & Recognition
Moffitt Cancer Center hosted the 2026 annual Mascots at Moffitt Day event featuring the Tampa Bay Buccaneers, Tampa Bay Lightning, and University of South Florida Bulls.
Reported by Bichoy Gabra
Research & Knowledge
Moffitt Cancer Center is testing a personalized mRNA vaccine approach in melanoma patients to prevent recurrence after surgery.
Reported by Bichoy Gabra
Research & Knowledge
Moffitt Cancer Center published results from a Phase 3 clinical trial showing that a personalized mRNA vaccine prevents melanoma recurrence in half after five years.
Reported by Bichoy Gabra
Legal & Regulatory
Moffitt Cancer Center's Office of General Counsel plays an important role in helping the organization advance its mission while navigating the complex legal and regulatory landscape of health care and research.
Reported by Patrick Hwu
Research & Knowledge
Moffitt Cancer Center published a multicenter real-world study evaluating bispecific antibodies in 122 patients with primary or secondary plasma cell leukemia, showing talquetamab had encouraging response and survival outcomes.
Reported by Omar Alexis Castaneda Puglianini
Products & Services
Moffitt Cancer Center announced that Aquablation offers a minimally invasive, robotic approach to treat enlarged prostates.
Reported by Moffitt Cancer Center
Research & Knowledge
Moffitt Cancer Center researcher Chip Atkins discussed how genetic engineering can give T cells new armor to survive inside tumors and better attack cancer in a Cancer Science Made Simple post.
Reported by Patrick Hwu
Products & Services
Moffitt Cancer Center is introducing Value Governance, an accountability architecture designed to track and measure the outcomes of healthcare investments.
Reported by Roderick Harris, MBA